CHANTAL TCHOUMBA: Open Payments
NPI 1962917864 · GLEN BURNIE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$597 in 26 payments from 5 companies in 2025. Trend: 2023 $146 · 2024 $446 · 2025 $597
Food & beverage: $597
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 15 | $350 |
| ABBVIE INC. | 7 | $179 |
| Lundbeck LLC | 2 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| E.R. Squibb & Sons, L.L.C. | 1 | $18 |
Products named: INGREZZA, VRAYLAR, ABILIFY ASIMTUFII, REXULTI, COBENFY.
Industry payments across MD — which companies pay providers there.
